Search: onr:"swepub:oai:DiVA.org:uu-380502" > Association between...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04780naa a2200493 4500 | |
001 | oai:DiVA.org:uu-380502 | |
003 | SwePub | |
008 | 190423s2019 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3805022 URI |
024 | 7 | a https://doi.org/10.3390/cancers110201732 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Toxopeus, Eelke L. A.u Erasmus Univ, Med Ctr, Dept Surg, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut |
245 | 1 0 | a Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer |
264 | c 2019-02-01 | |
264 | 1 | b MDPI,c 2019 |
338 | a electronic2 rdacarrier | |
520 | a Inter-individual variability in paclitaxel pharmacokinetics may play a role in the response to chemotherapy. Therefore, we studied the association between paclitaxel clearance and treatment response in patients with esophageal cancer. All patients who received paclitaxel (plus carboplatin) treatment for esophageal cancer between 2007 and 2013 were included. The treatment was given as neoadjuvant chemoradiotherapy (nCRT), induction chemotherapy (iCT), or palliative chemotherapy (pCT). The treatment response was assessed by the tumor regression grade (TRG) or by the RECIST1.1 criteria, respectively. The unbound paclitaxel clearance (CL) was estimated with NONMEM. The log-transformed clearance was related to response with ANOVA and independent sample t-tests. A total of 166 patients were included, of whom 113 received nCRT, 23 iCT and 30 pCT. In patients receiving nCRT, paclitaxel clearance was not associated with tumor regression grade (p-value = 0.25), nor with pathologically complete response (geometric mean 561.6 L/h) and residual disease (geometric mean 566.1 L/h, p-value = 0.90). In patients who underwent iCT or pCT, also no association between paclitaxel clearance and RECIST outcome was identified (iCT: p-value = 0.08 and pCT: p-value = 0.81, respectively). In conclusion, systemic paclitaxel exposure was not associated with response to common paclitaxel-based treatment regimens for esophageal cancer. Future studies should focus on tumor exposure in relation to systemic exposure and treatment outcome. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
653 | a paclitaxel | |
653 | a esophageal cancer | |
653 | a treatment response | |
653 | a pharmacokinetics | |
700 | 1 | a de Man, Femke M.u Erasmus Univ, Erasmus Med Ctr, Med Ctr, Canc Inst,Dept Med Oncol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut |
700 | 1 | a Krak, Nandau Erasmus Univ, Med Ctr, Dept Radiol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut |
700 | 1 | a Biermann, Katharinau Erasmus Univ, Med Ctr, Dept Pathol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut |
700 | 1 | a Nieuweboer, Annemieke J. M.u Erasmus Univ, Erasmus Med Ctr, Med Ctr, Canc Inst,Dept Med Oncol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut |
700 | 1 | a Friberg, Lena E.u Uppsala universitet,Institutionen för farmaceutisk biovetenskap4 aut0 (Swepub:uu)lenasimo |
700 | 1 | a Oomen-de Hoop, Estheru Erasmus Univ, Erasmus Med Ctr, Med Ctr, Canc Inst,Dept Med Oncol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut |
700 | 1 | a van Lanschot, Jan J. B.u Erasmus Univ, Med Ctr, Dept Surg, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut |
700 | 1 | a Shapiro, Joelu Erasmus Univ, Med Ctr, Dept Surg, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut |
700 | 1 | a Wijnhoven, Bas P. L.u Erasmus Univ, Med Ctr, Dept Surg, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut |
700 | 1 | a Mathijssen, Ron H. J.u Erasmus Univ, Erasmus Med Ctr, Med Ctr, Canc Inst,Dept Med Oncol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 aut |
710 | 2 | a Erasmus Univ, Med Ctr, Dept Surg, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlandsb Erasmus Univ, Erasmus Med Ctr, Med Ctr, Canc Inst,Dept Med Oncol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands4 org |
773 | 0 | t Cancersd : MDPIg 11:2q 11:2x 2072-6694 |
856 | 4 | u https://doi.org/10.3390/cancers11020173y Fulltext |
856 | 4 | u https://uu.diva-portal.org/smash/get/diva2:1306425/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print |
856 | 4 | u https://www.mdpi.com/2072-6694/11/2/173/pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-380502 |
856 | 4 8 | u https://doi.org/10.3390/cancers11020173 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view